Terms ending in 2041
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,007,393 | Methods Based on the Detection of RAD51 Foci in Tumor Cells Fundació Privada Institut d'Investigació Oncològica de Vall Hebron, AstraZeneca UK Limited and Xentech SAS In force · High confidence | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron, AstraZeneca UK Limited and Xentech SAS | In force | High confidence | |
| US 11,884,671 | Purinone Compounds and Their Use in Treating Cancer In force · High confidence | AstraZeneca AB and Cancer Research Technology Limited | In force | High confidence | |
| US 12,213,988 | Methods of Treating Chronic Kidney Disease with Dapagliflozin In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 12,409,186 | Methods of Treating Chronic Kidney Disease with Dapagliflozin In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 11,964,097 | Inhaler In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US D1,125,537 | Medical Injector In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US D1,126,392 | Inhaler In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,134,613 | Improved Method for the Manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,410,254 | Treatment of Cardiometabolic Disease with Inhibitors of Type I Interferon Signalling In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 11,952,392 | Arginase Inhibitors and Methods of Use thereof In force · High confidence | AstraZeneca AB | In force | High confidence | |
| 21 more term ends in 2041 · Pro | |||||
10 of 31 patents shown. Soonest term end first, then patent number.
Pro members see all 31.
27 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.